Asset
LISAFTOCLAX
ASCENTAGE PHARMA GROUP INTERNATIONAL AMERICAN DEPOSITORY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06389292 | phase3 | recruiting | 2024-06-11 | 2028-05-25 | Ascentage Pharma Group Inc. | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia |
| NCT04496349 | phase2 | recruiting | 2021-07-12 | 2026-05-31 | Ascentage Pharma Group Inc. | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL |
| NCT06182969 | phase1_2 | recruiting | 2024-08-09 | 2026-04-01 | Ascentage Pharma Group Inc. | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. |
| NCT06319456 | phase3 | recruiting | 2024-04-07 | 2027-08-01 | Ascentage Pharma Group Inc. | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
| NCT03913949 | phase1 | active_not_recruiting | 2019-06-03 | 2024-10-20 | Ascentage Pharma Group Inc. | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies |
FDA applications (0)
This company has no applications containing this asset.